Comparative evaluation of platelet-rich plasma and prolotherapy Injections in knee osteoarthritis: A randomized controlled trial
Satyendra Singh Yadav, Manish Kumar Singh, Pallavee Priyadarshini, Sarita Singh
Author(s)Abstract
Background: Knee osteoarthritis (OA) is a common degenerative joint disorder that impairs mobility and quality of life and has a rising prevalence in India. Platelet-rich plasma (PRP) and prolotherapy (PRL) are minimally invasive regenerative interventions. This study compared the effects of platelet-rich plasma (PRP) and prolotherapy (PRL) on pain relief and functional improvement in patients with grade I-II knee osteoarthritis (OA). Material and Methods: This single-blind randomized controlled trial enrolled Sixty-four patients aged 40-70 years with radiographically confirmed Kellgren-Lawrence grade I-II OA, who were randomized equally into groups A (PRP) and B (PRL). The interventions were administered intra-articularly under aseptic conditions. Pain and functional outcomes were evaluated using the Visual Analog Scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at baseline, weekly from weeks 1-6 months. Data were analyzed using SPSS v21.0. Results: Both groups showed significant reductions in the VAS and WOMAC scores over time (p<0.001). However, Group A (PRP) demonstrated significantly greater improvement than Group B (PRL) at each follow-up point after the baseline. At 6 months, PRP reduced VAS by a mean of -3.41 (95% CI -3.9 to -2.9) compared with -2.88 in PRL (p=0.0012). Mean WOMAC at 6 months was 30.28±4.78 (PRP) vs 38.31±4.88 (PRL), p<0.0001. Fewer patients in the PRP group required repeated doses (28% vs. 75%, p=0.0002) rescue analgesia (21.88% vs. 46.88%, P =0.0353). The side effect profiles were comparable. Conclusion: PRP demonstrated superior efficacy over prolotherapy and may be the preferred injectable option for early-stage OA; however, larger multicenter studies are needed.
Keywords: Knee osteoarthritis, platelet-rich plasma, prolotherapy, VAS, WOMAC, regenerative therapy.